Analyst Ratings For Editas Medicine Inc (NASDAQ:EDIT)
Today, Chardan Capital reiterated its Buy rating on Editas Medicine Inc (NASDAQ:EDIT) with a price target of $55.00.
There are 5 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Editas Medicine Inc (NASDAQ:EDIT) is Hold with a consensus target price of $47.4286 per share, a potential 81.44% upside.
Some recent analyst ratings include
- 1/22/2019-Editas Medicine Inc (NASDAQ:EDIT) had its Buy rating reiterated by Chardan Capital with a $55.00 price target
- 1/10/2019-Editas Medicine Inc (NASDAQ:EDIT) had its Hold rating reiterated by JPMorgan Chase & Co.
- 12/31/2018-Editas Medicine Inc (NASDAQ:EDIT) had its Buy rating reiterated by SunTrust Banks
- 10/9/2018-Editas Medicine Inc (NASDAQ:EDIT) has coverage initiated with a Neutral ➝ Neutral rating
- 9/21/2018-Editas Medicine Inc (NASDAQ:EDIT) has coverage initiated with a Outperform ➝ Outperform rating and $40.00 price target
- 3/14/2018-Editas Medicine Inc (NASDAQ:EDIT) had its Equal Weight ➝ Equal Weight rating reiterated by Morgan Stanley with a $43.00 price target
- On 1/18/2019 Vickesh Myer, Insider, sold 7,000 with an average share price of $26.36 per share and the total transaction amounting to $184,520.00.
- On 1/8/2019 Katrine Bosley, CEO, sold 12,000 with an average share price of $25.27 per share and the total transaction amounting to $303,240.00.
- On 1/4/2019 Andrew A F Hack, CFO, sold 7,000 with an average share price of $22.48 per share and the total transaction amounting to $157,360.00.
- On 12/18/2018 Vickesh Myer, Insider, sold 7,000 with an average share price of $27.61 per share and the total transaction amounting to $193,270.00.
- On 12/3/2018 Katrine Bosley, CEO, sold 12,000 with an average share price of $31.92 per share and the total transaction amounting to $383,040.00.
- On 11/23/2018 Andrew A F Hack, CFO, sold 5,284 with an average share price of $28.15 per share and the total transaction amounting to $148,744.60.
- On 11/20/2018 Vickesh Myer, CTO, sold 4,000 with an average share price of $26.50 per share and the total transaction amounting to $106,000.00.
About Editas Medicine Inc (NASDAQ:EDIT)
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Recent Trading Activity for Editas Medicine Inc (NASDAQ:EDIT)
Shares of Editas Medicine Inc closed the previous trading session at 26,14 −0,070 0,27 % with shares trading hands.